Liquidia Corporation will present two oral presentations at the CHEST 2025 annual meeting, focusing on clinical data from its ASCENT trial for LIQ861 DPI treprostinil in pulmonary hypertension-interstitial lung disease (PH-ILD) patients, highlighting safety and exploratory efficacy data.

The Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) market is expected to grow significantly between 2025-2034, driven by improved diagnostic techniques, disease recognition, and emerging therapies targeting functional improvement and disease progression.

The U.S. FDA has approved Liquidia's YUTREPIA, an inhaled dry-powder formulation of treprostinil, for the treatment of PAH and PH-ILD. The approval is based on the INSPIRE trial, which demonstrated YUTREPIA's safety, tolerability, and efficacy.

Liquidia Corporation announced that United Therapeutics filed a complaint alleging infringement of a patent related to inhaled treprostinil. Liquidia stated it has invalidated similar claims in the past and will continue to defend patients' access to its therapy.

The U.S. District Court for the District of Columbia dismissed a cross-claim filed by United Therapeutics that sought to challenge Liquidia's amendment to its New Drug Application for YUTREPIA, which added the treatment of pulmonary hypertension associated with interstitial lung disease to the proposed label. Liquidia remains focused on the potential final approval of YUTREPIA following the expiration of regulatory exclusivity.

Liquidia Corporation, a biopharmaceutical company, announced that it will report its full year 2024 financial results and provide a corporate update on March 19, 2025. The company is focused on developing innovative therapies for patients with rare cardiopulmonary diseases, including pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.

Atea Pharmaceuticals, a clinical-stage biopharmaceutical company, announced the appointment of Arthur S. Kirsch to its Board of Directors. Kirsch has extensive experience in investment banking and capital markets, as well as knowledge of the healthcare and life sciences industries.

The article discusses the evolving landscape of rare cardiovascular diseases, including Giant-Cell Arteritis, Pulmonary Arterial Hypertension, and Restrictive Cardiomyopathy. It highlights the challenges in diagnosis and treatment, as well as the growing market size and pipeline of new therapies for these conditions.

The U.S. Supreme Court has denied United Therapeutics' petition to appeal rulings that found all claims of its '793 patent invalid. This clears the way for Liquidia to launch its YUTREPIA drug for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.

Liquidia and Pharmosa Biopharm have expanded their collaboration to develop a sustained-release inhaled treprostinil (L606) for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The agreement expands Liquidia's licensed territory and grants it rights to Pharmosa's next-generation nebulizers.

The U.S. FDA has granted tentative approval for Liquidia's YUTREPIA (treprostinil) inhalation powder to treat adults with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). However, the final approval is delayed due to regulatory exclusivity granted to a competing product.

Liquidia Corp's Chief Medical Officer, Rajeev Saggar, has sold 1,470 shares of the company's common stock for $18,419, pursuant to a pre-scheduled 10b5-1 trading plan. The sale was to cover taxes associated with the vesting of restricted stock units.